CD4 and acute myeloid leukemia: Moreover, peptide-specific CD4+ memory T cells targeting a panel of HLA class II presented t-neopeptides (n = 9) identified in the immunopeptidomics analysis of the AML patients, were identified in one out of the eight AML patients that had undergone DNMTi treatment in vivo (Fig. 6f, Supplementary Data 12, 13).